Pharma-backed MinervaX raises €54M as it aims to move its group B Streptococcus vaccine into PhIII
Nearly a year after raising its largest financing so far, the Danish biotech MinervaX is back with an upsized financing round of €54 million ($57.3 million) to fund late-stage work for its vaccine against group B Streptococcus, the company announced Wednesday.
Group B Streptococcus is a bacteria responsible for nearly 50% of all life-threatening infections in newborns. It can also lead to other problems in pregnancy, like stillbirths, according to MinervaX.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.